Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Paragon Bioservices Wins Pfenex Contract | Contract Pharma
Breaking News

Paragon Bioservices Wins Pfenex Contract

To provide cGMP manufacture of rPA-based anthrax vaccine

Pfenex, Inc. has awarded Paragon Bioservices a contract for the cGMP manufacture of its rPA-based anthrax vaccine. Paragon will implement the cGMP-ready Pfenex Expression Technology-based production process that has been developed at Pfenex. The contract will be funded by the Department of Health and Human Services (HHS), through the Biomedical Advanced Research and Development Authority (BARDA).
 
“We are pleased to award this contract to Paragon Bioservices,” said Bertrand C. Liang, chief executive officer. “This is the next step in reaching our common objective with BARDA to develop an anthrax vaccine with a product capable of achieving the goals of the Strategic National Stockpile for the U. S. Government, including cost, shelf life, and administration improvements. With Paragon Bioservices we believe we will rapidly implement the large-scale cGMP production of the rPA required for our Phase I trial.”
 
Marco A. Chacon, Ph.D., chief executive officer of Paragon said, “My team and I are dedicated to providing manufacturing support to Pfenex, using their powerful protein expression technology. This project becomes all the more important since it will enrich the national armamentarium of vaccines against potential bio-weapons.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters